GLOW Peptide Stack (BPC-157 + TB-500 + GHK-Cu)

GLOW is a pre-mixed three-peptide compounded blend — typically GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg in a single 70 mg vial — sold by compounding pharmacies and peptide clinics as a one-injection recovery and skin-rejuvenation stack. It is one of the most-searched pre-mixed peptide blends in the biohacking and aesthetic wellness space, and the three components are chosen specifically to cover three distinct, non-overlapping phases of tissue repair. GLOW's three-layer repair logic. BPC-157 promotes systemic healing through angiogenesis and growth factor modulation — it drives blood vessel formation and inflammatory resolution at injury sites. TB-500 (the synthetic analog of the active region of thymosin beta-4) regulates actin polymerization, which underpins cell migration, wound closure, and progenitor-cell recruitment into damaged tissue. GHK-Cu (copper peptide) supports structural tissue remodeling — collagen synthesis, extracellular matrix organization, and fibroblast activity, with bioavailable copper feeding lysyl oxidase crosslinking that gives repaired collagen its tensile strength. Put together: BPC-157 builds the vascular and growth-factor substrate, TB-500 migrates cells into that substrate, and GHK-Cu organizes and crosslinks the new collagen matrix. The two-peptide variant (BPC-157 + GHK-Cu). Some practitioners source BPC-157 and GHK-Cu as separate vials without TB-500. This two-peptide pairing still delivers the healing + structural-rebuilding combination and gives more control over individual dosing and the ability to cycle components independently, but it loses TB-500's cell-migration layer. GLOW is the convenience-and-breadth version (one injection, three peptides at a fixed 5:1:1 ratio); the separate-vial approach is the flexibility version. Both map to the same broad use cases — musculoskeletal injury, post-surgical healing, skin rejuvenation, wound healing, scar reduction — with GLOW trading titration flexibility for the added third mechanism.

BPC-157 upregulates VEGF, EGF, and FGF expression, promoting angiogenesis and granulation tissue formation. It modulates the nitric oxide system and has demonstrated cytoprotective and anti-inflammatory effects across multiple tissue types. TB-500 (thymosin beta-4 analog) binds G-actin and regulates actin polymerization, which underpins cell migration, wound closure, and progenitor-cell recruitment into damaged tissue. It has been studied extensively in cardiac, dermal, and neural repair models, where its actin-sequestering activity drives the structural reorganization that follows vascularization. GHK-Cu works through a third distinct mechanism — as a copper-binding tripeptide, it activates tissue remodeling genes involved in collagen I and III synthesis, glycosaminoglycan production, and metalloproteinase regulation. It recruits fibroblasts and mast cells to repair sites and has demonstrated antioxidant and anti-inflammatory properties independent of its copper delivery. The bioavailable copper also feeds lysyl oxidase crosslinking, the step that gives repaired collagen its tensile strength. The proposed complementarity at the heart of GLOW: BPC-157 creates the vascular infrastructure and growth factor environment for healing, TB-500 drives cell migration into that substrate, and GHK-Cu organizes and crosslinks the new matrix. A 2026 review of therapeutic peptides in orthopaedics specifically covers BPC-157, TB-500, and GHK-Cu as complementary regenerative agents.

Both peptides have substantial preclinical evidence individually. BPC-157 has hundreds of animal studies demonstrating tissue repair effects across tendon, muscle, gut, and bone — though human clinical trial data remains very limited. A 2026 review characterized it as promising for regeneration and pain management. GHK-Cu has both preclinical and clinical evidence for skin applications. A 2023 study demonstrated synergy between GHK-Cu and hyaluronic acid for collagen IV upregulation in fibroblast and ex-vivo skin models. Multiple studies confirm its wound healing and anti-aging properties. For the GLOW variant, TB-500 adds a third evidence base — extensive preclinical work in cardiac, skin, and neural repair centered on actin regulation and cell migration, with human data limited to case reports and small open-label series. Neither the BPC-157 + GHK-Cu two-peptide combination nor the GLOW three-peptide formulation has been tested in published human clinical trials; the rationale at every level is built from component pharmacology rather than combination-level outcomes.

Separate-vial sourcing. BPC-157 is typically administered via subcutaneous injection for systemic or localized recovery applications. GHK-Cu is available in both injectable and topical forms — injectable for systemic recovery, topical for skin-focused applications. When combined for recovery, both may be injected subcutaneously. For skin applications, GHK-Cu is often used topically while BPC-157 is injected. GLOW (pre-mixed). The 70 mg GLOW vial (GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg) is typically reconstituted in 2 mL of bacteriostatic water, yielding 35 mg/mL total peptide at a fixed 5:1:1 ratio (GHK-Cu:BPC-157:TB-500). Common practitioner protocols run 0.2–0.4 mL (7–14 mg total peptide) subcutaneously 3–5 times per week for 4–8 weeks, with some clinics using a loading phase (daily for the first 1–2 weeks) then tapering. Abdominal fat pad is the standard injection site. Cycling — 4–8 weeks on, 2–4 weeks off — is conventional, driven in part by GHK-Cu's copper-delivery component and the general caution around long-duration compounded peptide use. Specific protocols should be determined by a qualified clinician.